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Abstract
Background: CD7 is a negative prognostic marker in myeloid malignancies. In acute myeloid leukemia (AML), an 
inverse correlation exists between expression of wild-type CEBPA and CD7. Aim of this study was to find out whether C/
EBPα is a negative regulator of CD7 and which other regulatory mechanisms might be involved.
Results: As already described for primary AML cells, the majority of AML cell lines tested were either C/EBPα+/CD7- or 
C/EBPα-/CD7+. However, the existence of isolated CD7+ cell lines expressing wild-type C/EBPα challenges the notion 
that C/EBPα acts as a unique repressor of CD7. Furthermore, ectopic expression of CEBPA did not reduce CD7 in CD7+ 
cells and knock-down of C/EBPα failed to induce CD7 in CD7- cells. In contrast, the DNA demethylating agent Aza-
2'deoxycytidine triggered CD7 expression in CD7- AML and in T-cell lines suggesting epigenetic regulation of CD7. 
Bisulfite sequencing data confirmed that CpGs in the CD7 exon1 region are methylated in CD7- cell lines, and 
unmethylated in CD7+ cell lines.
Conclusion: We confirmed an inverse correlation between the expression of wild-type CEBPA and of CD7 in AML cells. 
Our results contradict the hypothesis that C/EBPα acts as repressor for CD7, and instead show that epigenetic 
mechanisms are responsible for CD7 regulation, in AML cells as well as in T-cells, the typical CD7 expressing cell type.
Background
CCAAT/enhancer binding factor alpha (CEBPA), located
on chromosome 19q13.1 encodes a transcription factor
that is of importance for granulocytic differentiation [1].
C/EBPα is upregulated during myelomonocytic develop-
ment and positively affects expression of granulocyte dif-
ferentiation related genes such as the G-CSF receptor
(GCSFR),  myeloperoxidase  and  neutrophil elastase
(ELA2) [2-4]. CEBPA mutations are found in 5 - 14% of
acute myeloid leukemia (AML) cases [5]. C/EBPα mutant
proteins block the effect of wild-type C/EBPα on target
genes in a dominant-negative manner [6]. This might be
the reason why patients with CEBPA mutations and those
with a silenced CEBPA promoter are found in the same
AML subclass according to gene expression profiling [7].
Also expression of the T-cell marker CD7 has been asso-
ciated with CEBPA mutations and with CEBPA hyperm-
ethylation [7,8].
CD7 is expressed in 30% of AML cases and CD7 posi-
tivity is linked with poor prognosis in myeloid malignan-
cies [9,10]. In healthy individuals, CD7 is expressed on
thymocytes, T- and natural killer cells, and progenitors of
lymphoid and myeloid cells [10]. Conditional knockout
experiments in mice suggest that Cebpa is involved in the
regulation of Cd7 expression: absence of Cebpa results in
upregulation of Cd7 in mouse hematopoetic stem cells,
reintroduction of the transcription factor reduces expres-
sion of Cd7 [7].
We wanted to find out whether CD7 positivity in AML
can be explained as consequence of loss or inactivation of
wild-type  CEBPA. Therefore, we externally regulated
CEBPA expression in AML cell lines and tested whether
and how this treatment affected CD7 expression.
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Results and discussion
CEBPA expression and CD7 silencing
Quantitative real-time PCR (qRT-PCR) analysis showed
that 42% (23/54) of the AML cell lines tested were CD7
positive with expression levels comparable to those of T-
cell lines, 28% (15/54) of cell lines were weakly positive
and 30% (16/54) were CD7 negative.
On the first view, Western blot analyses confirmed that
C/EBPα might be a negative regulator for CD7 expression
in AML cell lines: most cell lines showed mutually exclu-
sive expression of these proteins, being either C/EBPα+/
CD7- or C/EBPα-/CD7+ (Fig. 1A, Table 1). However, there
was one noticeable exception: cell line HNT-34 expressed
both proteins, C/EBPα and CD7, challenging the auto-
matic linkage of C/EBPα expression to CD7 repression
(Fig. 1A, Table 1).
Furthermore, it remained open as to how the transcrip-
tion factor C/EBPα could inhibit expression of CD7. The
search for transcription factor binding sites using bioin-
formatic databases (TFSEARCH and TESS) did not
reveal a potential C/EBPα binding site in the CD7 pro-
moter region (-713 to +624). A report describing that c-
Myc expression was negatively regulated by C/EBPα via
an E2F binding site [11] indicates the possibility of a C/
EBPα-mediated transcriptional gene regulation by pro-
tein/protein interaction. CD7 exon 1 also contains an E2F
binding site according to TFSEARCH results. To test
whether C/EBPα acts as direct or indirect transcriptional
repressor for CD7 - by protein/DNA or by protein/pro-
tein interaction - we checked our cell lines for any C/
EBPα/CD7mRNA correlation. Analysis of C/EBPα pro-
tein and CD7 mRNA expression showed an even weaker
correlation than the protein/protein analysis: 3/25 cell
lines (HNT-34, IMS-M1, ME-1) were C/EBPα-positive
and still showed high expression levels of CD7 mRNA
(Table 2).
We sequenced the CEBPA gene to find out whether
CD7 expression in these three cell lines might result from
inactivating  CEBPA  mutations. Two of the three C/
EBPα+/CD7+ cell lines (HNT-34, IMS-M1) carried and
expressed an in-frame CEBPA mutation resulting in four
(instead of three) histidine-proline repeats in the transac-
tivation domain 2 of the protein. However, this mutation
is considered insignificant for leukemogenesis as it was
detected in 39% of healthy volunteers and in 20% of AML
patients who remained positive after complete remission
[8]. Accordingly, 7/25 (28%) cell lines in our study carried
this length polymorphism. Sequencing revealed that
none of the three C/EBPα positive and CD7 mRNA posi-
tive cell lines showed an inactivating CEBPA aberration.
Furthermore, cell line ME-1 did not carry any mutation at
all, showing that the CD7  gene could be transcribed
despite expression of wild-type C/EBPα.
No direct influence of C/EBPα on expression of CD7
We had started this project to find out whether CD7 pos-
itivity in AML might be due to loss or inactivation of
wild-type  CEBPA. In line with the idea of a repressor
function for C/EBPα was the observation that most cell
lines showed an inverse correlation between C/EBPα and
CD7 expression (Table 2). However, 3/25 cell lines (HNT-
34, IMS-M1, ME-1) were C/EBPα+ and still expressed
CD7  mRNA. C/EBPα/CD7 double positivity does not
necessarily contradict a repressor function of C/EBPα.
Cell lines HNT-34, IMS-M1 and ME-1 might carry addi-
tional genetic or epigenetic alterations not allowing a
"normal" repressor function of C/EBPα in these cell lines.
To experimentally test whether C/EBPα has a direct
inhibitory effect on CD7 expression, we first ectopically
expressed  CEBPA in the C/EBPα-/CD7+ cell line CMY
and then knocked down C/EBPα in the C/EBPα+/CD7-
cell line NB-4 (Table 2). In both cell lines, expression of
the transcriptional C/EBPα targets GCSFR and ELA2 was
positively correlated with CEBPA expression levels (Fig.
2). In contrast, CD7 mRNA levels were neither positively
nor negatively affected by C/EBPα (Fig. 2). These results
Figure 1 C/EBPα and CD7 protein expression. Western blot analy-
ses were performed to detect C/EBPα and CD7 in (A) AML cell lines and 
in (B) T-cell lines. GAPDH was used as protein loading control. Note that 
the AML cell line HNT-34 expresses C/EBPα and CD7 and that T-cell 
lines can be C/EBPα-/CD7-.
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contradict the hypothesis that C/EBPα acts as CD7 sup-
pressor.
Epigenetic regulation of CD7
Study of T-cell lines confirmed that CD7 repression can
occur in the absence of C/EBPα: T-cell lines are C/EBPα-
negative, but not all T-cell lines express CD7 (Fig. 1B).
The CD7 promoter region does not match the criteria of
a standard CpG island with a GC content > 50% and an
observed CpG/expected CpG ratio > 0.6 [12]. However,
according to the criteria of Weber et al. [13] the CD7
exon 1 region contains a subthreshold CpG island (inter-
Table 1: C/EBPα and CD7 expression in AML cell lines
C/EBPα CD7 neg CD7 low CD7 high
n e g 019
l o w 111
high 10 1 1
Inverse correlation between C/EBPα and CD7 protein expression in 25 AML cell lines as assessed by Western blot analysis. Cell lines classified 
as "low" showed faint signals, "high" denotes all positive signals in Fig. 1. GAPDH was used as protein loading control. Note that one cell line 
(HNT-34) expressed C/EBPα (high) and CD7 (high).
Table 2: C/EBPα and CD7 expression in individual AML cell lines
Cell lines CEBPA mRNA C/EBPα protein CD7 mRNA CD7 protein
AP-1060 + + - -
CMK (+) - + +
CMY - - + +
F-36P - - + +
GDM-1 (+) - + +
HL-60 + + - -
HNT-34 ++++
HT-93A + + - -
IMS-M1 +++-
KG-1 (+) - + +
M-07e - - + +
ME-1 +++-
MEGAL (+) - + +
MOLM-16 - - + +
MONO-MAC-6 + + (+) -
MUTZ-8 + + (+) (+)
NB-4 + + - -
OCI-AML2 + + - -
OCI-AML5 + + - -
OCI-M1 (+) (+) - (+)
OCI-M2 (+) - - (+)
SET-2 (+) (+) + +
SIG-M5 + + - -
SKNO-1 (+) (+) (+) -
TF-1 - - + +
C/EBPα and CD7 Western blot analysis: + positive, (+) weakly positive, - negative. GAPDH was used as protein loading control. CEBPA qRT-PCR: 
+: 2^-ΔΔct ≥ 5.0; (+) 2^-ΔΔct ≥ 0.2, < 5.0; -: 2^-ΔΔct < 0.2. The CEBPA-low cell line SET-2 was used as calibrator cell line. CD7 qRT-PCR: +: 2^-
ΔΔct > 2.5; (+) 2^-ΔΔct ≥ 1; -: 2^-ΔΔct < 1. The CD7-low cell line MUTZ-8 was used as calibrator cell line. Note that cell lines HNT-34, IMS-M1 
and ME-1 (bold) express C/EBPα and CD7 mRNA.Röhrs et al. Journal of Hematology & Oncology 2010, 3:15
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mediate CpG promoter) with moderate CpG richness
(observed CpG/expected CpG ratio > 0.2) and high GC
content (> 60%) suggesting that the gene might be epige-
netically regulated. Methylation-specific PCR (MSP) and
sequencing of bisulfite-converted DNA revealed that this
site was methylated in CD7-negative T-cell lines, while
CD7-positive T-cell lines were not methylated around the
transcriptional start site (Fig. 3, 4). These data support a
recent study linking CD7 expression to chromatin modi-
fications in CML [14]. Also in AML, unmethylated cell
lines (unmethylated signal U only) expressed CD7 (2/2),
while methylated cell lines (methylated signal M only)
were CD7-negative (8/9) or weakly positive (1/9) (Table
3). Furthermore, a DNA demethylating agent induced
CD7 expression in CD7-methylated cell lines, indepen-
dent of histological origin: the T-anaplastic large cell lym-
phoma-derived cell line SR-786 and the AML cell line
HL-60 each showed a ca. 30-fold increase of CD7 expres-
sion after treatment with 5-Aza-2'-deoxycytidine (Aza),
while unmethylated cell lines (ALL-SIL, F-36P, GDM-1)
were unaffected (Fig. 4). These results suggest that epige-
netic mechanisms play a role in the regulation of CD7,
both in T-cell lines and in AML cell lines: (i) we found a
negative correlation between CD7 promoter methylation
and gene expression, and (ii) observed that a demethylat-
ing agent induced CD7 expression in silenced cell lines.
Interestingly four cell lines (IMS-M1, ME-1, MONO-
MAC-6, SKNO-1) were CD7 mRNA positive but did not
express CD7 protein (Table 2). Future studies might show
which posttranscriptional mechanisms - including possi-
bly translational inhibition by microRNAs - are responsi-
ble for this phenomenon.
Conclusions
An inverse correlation between CD7  methylation and
CD7 expression was observed in T-cell lines as well as in
AML cell lines suggesting that in both lineages epigenetic
mechanisms underlie CD7 regulation. Two observations
imply that other factors are also important for CD7
expression: (i) the stimulating effect of Aza on CD7
expression levels varied substantially across different
CD7 methylated cell lines, and (ii) even cell lines that
were clearly responsive to Aza with respect to CD7
mRNA induction did not show upregulation of CD7 pro-
Figure 3 Epigenetic regulation of CD7. CD7 promoter methylation 
was analyzed by MSP after bisulfite conversion of the DNA. Agarose 
gels of CD7 M- and U-PCR products from T- and AML cell lines are 
shown as representative results.
T-lineage AML
CD7 MSP
CD7- CD7+    CD7- CD7+
T lineage            AML
Figure 2 C/EBPα does not affect CD7 mRNA expression. CEBPA was 
ectopically expressed in the CEBPA-negative cell line CMY and re-
pressed in the CEBPA-positive cell line NB-4. Expression levels were as-
sessed at day 4 (CEBPA RNAi) and day 13 (ectopic expression of CEBPA) 
by qRT-PCR. Gene names at the right-hand side of the figure apply for 
all four columns. Expression of the C/EBPα targets ELA2 and GCSFR de-
pends on CEBPA expression, CD7 mRNA levels are unaffected and re-
main positive in cell line CMY, negative (neg.) in cell line NB-4.
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tein as assessed by Western blot and FACS analysis (data
not shown). Although transfection studies did not indi-
cate that C/EBPα acts as CD7 repressor, the inverse cor-
relation between CEBPA and CD7 expression reported
for primary AML cases was confirmed for most AML cell
lines. Thus, future studies should address whether C/
EBPα is a second factor responsible for repression of CD7
besides promoter methylation.
Methods
Human cell lines
T h e  c o n t i n u o u s  c e l l  l i n e s  w e r e  e i t h e r  t a k e n  f r o m  t h e
stock of the cell bank (DSMZ - German Collection of
Microorganisms and Cell Cultures) or were generously
provided by the original investigators. Detailed references
and cultivation protocols have been described previously
[15].
Methylation-specific polymerase chain reaction (MSP)
Bisulfite conversion of DNA was performed as described
by the supplier (EpitTect Bisulfite Kit, Qiagen, Hilden,
Germany). For detecting CD7 promoter methylation, we
performed nested PCR with first round primers (CD7
BSP fwd 5'-TTT TGT GGA GAT GTA GGG GTA-3',
CD7 BSP rev 5'-CAC CAT CAA TCT AAC CAA AAA
AAC-3') amplifying converted DNA independently of the
methylation status (bisulfite-specific PCR, BSP), while
second round primers (CD7 M fwd 5'-TTT TTG AGT
TTT GAG CGT TTG C-3', CD7 M rev 5'-AAA CAA
ACC GCG AAC CAA CG-3', CD7 U fwd 5'-GTT TTT
Figure 4 Bisulfite sequencing of CD7 exon 1 region. CpGs are represented as open dots (U = unmethylated) or filled dots (M = methylated). Name 
in red: CD7+ cell line, name in green: CD7- cell line. Numbers on the right hand side show the effect of Aza (3 d, 5 μM) on CD7 mRNA levels, as assessed 
by qRT-PCR. Note that Aza induces CD7 expression in methylated cell lines (SR-786 and HL-60) only.
CD7 bisulfite sequencing
HL-60
SR-786
ATG
ALL-SIL
F-36P
GDM-1
MSP
exon 1 CD7
11 9 1
CMK
AML
T-lineage MSP
U
M/U
U
U
M
M/U
Aza
0.6x
31x
1x
0.6x
1x
31x
Table 3: CD7 promoter methylation and CD7 mRNA expression in AML cell lines
CD7 MSP CD7 mRNA negative CD7 mRNA low CD7 mRNA high
U002
U/M 1 2 11
M810
CD7 methylation was assessed by MSP. U: products with primers recognizing unmethylated CD7 only; U/M: U and M (methylated) products; 
M: M products only. CD7 mRNA expression was assessed by qRT-PCR and evaluated as described in Table 2. Note that 2/2 unmethylated (U 
only) cell lines are CD7-positive and that 8/9 methylated (M only) cell lines are CD7-negative. Methylation-specific (M) and unmethylation-
specific (U) PCR were very sensitive, allowing the detection of one methylated cell in 1000 unmethylated cells and vice versa. Therefore, a 
meaningful correlation between CD7 methylation and expression was not apparent in U/M cells.Röhrs et al. Journal of Hematology & Oncology 2010, 3:15
http://www.jhoonline.org/content/3/1/15
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TTT GAG TTT TGA GTG TTT GT-3', CD7 U rev 5'-
CCA AAC AAA CCA CAA ACC AAC A-3') for M- and
U-PCR specifically recognized the methylated or unm-
ethylated versions of the promoter. PCR products of the
initial BSP were diluted 1:100 for subsequent M- and U-
PCR. Annealing temperatures were 53°C for BSP with 35
cycles and 63°C for M- and U-PCR with 30 cycles each.
Epitect PCR Control DNA (Qiagen) was used as control
for methylated and unmethylated templates.
Bisulfite sequencing
To confirm the methylation status of the CD7 promoter,
DNA of cell lines was bisulfite converted according to the
manufacturer's instructions (Qiagen). Subsequently,
amplification of the CD7 exon 1 region (760 bp) was per-
formed using primers CD7 BSP fwd and CD7 BSP rev,
specifically binding bisulfite converted DNA (for primer
sequence and PCR conditions see MSP section). Result-
ing  CD7  fragments were purified, cloned into pGEM-
TEasy vector (Promega, Madison, WI, USA) and
sequenced. Sequences were evaluated using BiQ Ana-
lyzer http://biq-analyzer.bioinf.mpi-sb.mpg.de and had to
conform to at least 90% bisulfite conversion rate [16]. In
addition, identical clones were excluded from the analy-
sis.
Gene expression analyses
Quantitative PCR was performed on a 7500 Applied Bio-
systems (Darmstadt, Germany) real-time PCR system
using the manufacturer's protocol. RNA was prepared
using the RNeasy Mini kit (Qiagen). For mRNA quantifi-
cation, reverse transcription was performed using the
SuperScript II reverse transcriptase kit (Invitrogen,
Karlsruhe, Germany). TaqMan probes (Applied Biosys-
tems) were used to quantify human CEBPA  (Hs
00269972s1), ELA2 (Hs 00357734 m1) and GCSFR (Hs
01114427 m1) expression levels with TBP as endogenous
control. Expression of CD7 was assessed using the SYBR
GREEN PCR Master Mix (Applied Biosystems) with
GAPDH as internal control. CD7 forward: 5'-GTG CTG
GCG AGG ACA CAG-3'; CD7  reverse: 5'-TCG TAC
ACC ACA CAT GCC G-3'. GAPDH  forward: 5'-TGG
GTG TGA ACC ATG AGA AG-3'; GAPDH reverse: 5'-
TCC ACG ATA CCA AAG TTG TCA-3'. Relative expres-
sion levels were calculated using the ΔΔCt-method.
Treatment with DNA demethylating agent Aza
5-Aza-2'-deoxycytidine (Aza) (Sigma) dissolved in
DMSO was used to verify the effect of methylation on
expression of CD7. Cells were seeded at a cell density of 5
× 105 cells/ml, Aza was added at a final concentration of 5
μM. Control cells were treated with 0.05% DMSO. After 2
d, half of the medium was replenished with medium
with/without Aza (5 μM). After 3 d, respectively 4 d, cells
were harvested to prepare RNA or protein.
Western blot analysis
Samples were prepared as described previously [17]. Anti
CD7 antiserum was purchased from Santa Cruz (Heidel-
berg, Germany), anti C/EBPα antiserum was obtained
from Cell Signaling/New England Biolabs (Frankfurt,
Germany). Specific bands on nitrocellulose membranes
were visualized with the biotin/streptavidin-horseradish
peroxidase system (Amersham, Freiburg, Germany) in
combination with the "Renaissance Western Blot
Chemoluminescence Reagent" protocol (DuPont, Bad
Homburg, Germany).
Bioinformatic database search for C/EBPα binding sites
The genomic sequence of the CD7 promoter region from
-713 to +624 was analyzed with the database search tools
TFSEARCH ver.1.3 http://www.cbrc.jp/research/db/
TFSEARCH.html and TESS http://www.cbil.upenn.edu/
cgi-bin/tess/tess for the existence of potential C/EBPα
binding sites (Factor ID in TESS: T00105).
Plasmid construction
For generating the anti-CEBPA shRNA, DNA oligonucle-
otides corresponding to position 818-836 of the sequence
of the human CEBPA  gene (GenBank accession no.
NM_004364.3) were subjected to BLAST homology
search, and thereafter chemically synthesized including
overhang sequences from a 5'-BglII and a 3'-SalI restric-
tion site for cloning purposes (BioSpring, Frankfurt, Ger-
many). The numbering of the first nucleotide of the
shRNA refers to the A TG start codon. The oligonucle-
otide sequences were as follows: FPCEBPA: 5'-
GATCCCCGGCCAAGAAGTCGGTGGACTTCAAGA
GAGTCCACCGACTTCTTGGCCTTTTTTGGAAG-3';
RPC EBPA: 5'-CGACTTCCAAAAAAGGCCAA-
GAAGTCG GTGGACTCTCTTGAAGTCCACCGACT-
TCTTGGCCGGG-3'.
The non-complementary 9-nt loop sequences are
underlined, and each sense oligonucleotide harbors a
stretch of T as a PolIII transcription termination signal.
The oligonucleotides were annealed and inserted 3' of the
H1-RNA promoter into the BglII/SalI-digested pBlue-
Script-derived pH1-plasmid to generate pH1-CEBPA as
described [18]. The control plasmid pH1-GL4 has been
described earlier [18]. Finally, the H1-CEBPA expression
cassette was excised by digestion with SmaI and HincII
and blunt-end ligated into the SnaBI site of the pdc-SR
lentiviral vector to generate pdcH1-CEBPA-SR plasmid.
The lentiviral plasmid encodes RFPEXPRESS as reporter
gene.Röhrs et al. Journal of Hematology & Oncology 2010, 3:15
http://www.jhoonline.org/content/3/1/15
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Preparation of recombinant lentiviral supernatants and 
lentiviral transduction
Preparation of recombinant lentiviral supernatants and
transduction were performed as described previously
[18]. The titers were averaged and typically ranged
between 5-10 × 108 IU/ml. Concentrated viral superna-
tants were used for transduction of NB-4 cells in 48-well
plates as described [18].
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